

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Avesthagen partners with Wipro to launch genetic tests for cancers

20 June 2022 | News

The India launch will be followed by expansion in South Asia, Southeast Asia and the MENA region in Q4 2022



Bengaluru-based Avesthagen has entered into a four-year strategic alliance with Wipro for making its genetic testing portfolio commercial. The portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.

Together, Avesthagen and Wipro will execute the project titled, "Cancer Risk Assessed by NGS profiling of Circulating free DNA and RNA for Lung Cancer Project related Genomics Sequencing services."

The Project will be jointly led by Avesthagen and Wipro where Wipro's state-of-the-art Lifesciences lab will perform initial processing of the samples, generate data on the latest Next-generation sequencing platforms, compile genomic sequences and analyze detailed molecular information using computational AI/ML based tools.

Wipro's expertise across multi-disciplinary areas of genomics and biomarker discovery, will help Avesthagen in building well-regulated workflows during the development of CALiBRx gene panels. The tests would be predominantly offered in super specialty clinics and hospitals that focus on oncological disorders. It will later strategically release diagnostic tools that address upper respiratory cancers such as head, neck and esophageal cancers. In the medium and long term, the project would lead to a new generation of genome-led medicine.

CALiBRxO - the 624 gene panel - will be available in the market from Q3 2022 and will target cancers and neurological conditions. It presents a targeted screening approach of 624 genes implicated in oncological conditions.

The India launch will be followed by expansion in South Asia, Southeast Asia and the MENA region in Q4 2022. Over the next decade, it will license its IP and product outcomes to digital health, pharma and food companies and Fortune 500 biotech companies.